Acute Respiratory Distress Syndrome – Pipeline Review, 2019

Acute Respiratory Distress Syndrome (ARDS) occurs when fluid builds up in alveoli in the lungs. Patients with ARDS have a rapid onset of shortness of breath and very low oxygen levels in the blood. The symptoms vary in intensity, depending on severity and cause. Other symptoms include labored and unusually rapid breathing, severe shortness of breath, low blood pressure, and others. The most common underlying causes of ARDS are sepsis, inhalation of harmful substances, severe pneumonia, head, chest or other major injuries causing complications such as blood clots, collapsed lungs i.e. pneumothorax, infections, and pulmonary fibrosis.

The diagnosis of acute respiratory distress syndrome can be done with chest X-ray, computerized tomography, lab tests, electrocardiogram, echocardiogram, etc. Improving the level of oxygen in the blood is the primary target for the treatment of acute respiratory distress syndrome. This can be done using supplemental oxygen and mechanical ventilation. Medications in patients with acute respiratory distress syndrome are used to prevent and treat infections, relieve pain and discomfort, prevent blood clots in legs and lungs, minimize gastric reflux, and used to sedate patients.

 Academic research institutes and research laboratories have focused on studying and developing new treatment options for acute respiratory distress syndrome. For instance; HLCM051, which is being studied by HEALIOS K.K., is currently in phase-2 clinical trials for the study of safety and efficacy of HLCM051 patients with Pneumonic Acute Respiratory Distress Syndrome.

At present more than 70% of the pipeline candidates for ARDS are in the phase-2 and phase-3 stage. More than half of the ARDS clinical studies are sponsored by academic research institutes and research laboratories.

Report Description

The report on ‘Acute Respiratory Distress Syndrome – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Acute Respiratory Distress Syndrome. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acute Respiratory Distress Syndrome.

The report on ‘Acute Respiratory Distress Syndrome – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Acute Respiratory Distress Syndrome
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Acute Respiratory Distress Syndrome
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary